- Home
- CENX vs GLPG Comparison
CENX vs GLPG Comparison
Compare CENX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENX
- GLPG
- Stock Information
- Founded
- CENX 1995
- GLPG 1999
- Country
- CENX United States
- GLPG Belgium
- Employees
- CENX N/A
- GLPG N/A
- Industry
- CENX Aluminum
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CENX Industrials
- GLPG Health Care
- Exchange
- CENX Nasdaq
- GLPG Nasdaq
- Market Cap
- CENX 2.0B
- GLPG 2.1B
- IPO Year
- CENX 1996
- GLPG 2005
- Fundamental
- Price
- CENX $28.20
- GLPG $34.69
- Analyst Decision
- CENX Strong Buy
- GLPG Sell
- Analyst Count
- CENX 3
- GLPG 3
- Target Price
- CENX $25.00
- GLPG $26.00
- AVG Volume (30 Days)
- CENX 2.2M
- GLPG 199.1K
- Earning Date
- CENX 11-03-2025
- GLPG 10-29-2025
- Dividend Yield
- CENX N/A
- GLPG N/A
- EPS Growth
- CENX N/A
- GLPG N/A
- EPS
- CENX 1.20
- GLPG N/A
- Revenue
- CENX $2,432,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- CENX $17.06
- GLPG $1.77
- Revenue Next Year
- CENX $2.35
- GLPG $0.44
- P/E Ratio
- CENX $23.48
- GLPG N/A
- Revenue Growth
- CENX 15.38
- GLPG 5.43
- 52 Week Low
- CENX $13.05
- GLPG $22.36
- 52 Week High
- CENX $31.06
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- CENX 64.06
- GLPG 55.45
- Support Level
- CENX $28.81
- GLPG $32.37
- Resistance Level
- CENX $30.08
- GLPG $37.78
- Average True Range (ATR)
- CENX 1.44
- GLPG 0.85
- MACD
- CENX 0.07
- GLPG 0.20
- Stochastic Oscillator
- CENX 54.91
- GLPG 48.88
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.